Status:
COMPLETED
Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD
Lead Sponsor:
AstraZeneca
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
40+ years
Phase:
PHASE3
Brief Summary
This study aims at evaluating efficacy and safety of Symbicort® Turbuhaler® in Chinese COPD patients as defined by GOLD treatment guidelines in order to obtain an approval for indication of COPD from ...
Eligibility Criteria
Inclusion
- Signed and dated inform consent
- Out-patient, clinical diagnosis of COPD
- Men or women at the age of 40 or over
Exclusion
- A history of asthma
- Seasonal allergic rhinitis before 40 years of age
- Patients with significant or unstable ischemic heart disease, arrhythmia, cardiomyopathy, heart failure, uncontrolled hypertension as defined by the investigator or other disorder
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2007
Estimated Enrollment :
315 Patients enrolled
Trial Details
Trial ID
NCT00421122
Start Date
September 1 2006
End Date
November 1 2007
Last Update
March 27 2009
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Beijing, Beijing Municipality, China
2
Research Site
Guangzhou, Guangdong, China
3
Research Site
Nanjing, Jiangsu, China
4
Research Site
Shenyang, Liaoling, China